Harness, J
622  Ergebnisse:
Personensuche X
?
2

A review of machine learning in obesity:

DeGregory, K. W. ; Kuiper, P. ; DeSilvio, T....
Obesity Reviews.  19 (2018)  5 - p. 668-685 , 2018
 
?
4

Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, i..:

Mamolo, C. ; Harness, J. ; Tan, H..
Journal of the European Academy of Dermatology and Venereology.  28 (2013)  2 - p. 192-203 , 2013
 
?
6

Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,5..:

Tan, H ; Gupta, P ; Harness, J...
CPT: Pharmacometrics & Systems Pharmacology.  2 (2013)  5 - p. 1-8 , 2013
 
?
7

Effect of tofacitinib, a Janus kinase inhibitor, on haemato..:

Strober, B. ; Buonanno, M. ; Clark, J.D....
British Journal of Dermatology.  169 (2013)  5 - p. 992-999 , 2013
 
?
8

Efficacy and safety of tofacitinib, an oral Janus kinase in..:

Papp, K.A. ; Menter, A. ; Strober, B....
British Journal of Dermatology.  167 (2012)  3 - p. 668-677 , 2012
 
?
9

Can sebum reduction predict acne outcome?: Sebum reduction ..:

Janiczek-Dolphin, N. ; Cook, J. ; Thiboutot, D...
British Journal of Dermatology.  163 (2010)  4 - p. 683-688 , 2010
 
?
10

Increased levels of activated T-cells and reduced levels of..:

Harness, J. ; McCombe, P.A.
Journal of Clinical Neuroscience.  15 (2008)  9 - p. 1031-1035 , 2008
 
?
12

Childhood Thyroid Carcinoma:

, In: Textbook of Endocrine Surgery,
HARNESS, J - p. 93-101 , 2005
 
?
13

The Effects of Pregnancy on Myelin Basic Protein‐induced Ex..:

HARNESS, J. ; McCOMBE, P.A.
American Journal of Reproductive Immunology.  46 (2001)  6 - p. 405-412 , 2001
 
?
14

Ziprasidone and the pharmacokinetics of a combined oral con..:

Muirhead, G. J. ; Harness, J. ; Holt, P. R...
British Journal of Clinical Pharmacology.  49 (2000)  S1 - p. 49-56 , 2000
 
?
 
1-15